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A B S T R A C T
The rising threat of Antimicrobial Resistance (AMR) requires a novel approach to the treatment of infectious
diseases. Covalently bonded silver, which has known antibacterial and antifungal properties and multiple me-
chanisms of action, may provide a treatment strategy when used alone or in combination with already known
antimicrobial compounds. Here we describe the synthesis of eight novel silver(I) complexes, which were
screened for in vitro activity against two pathogenic bacterial strains, Methicillin-resistant Staphylococcus aureus
(MRSA) and Escherichia coli (E. coli), and against two pathogenic fungal strains, Candida albicans and Candida
parapsilosis. Complexes 5–8 were synthesized by reacting triphenylphosphine in relative equivalents with the
relevant silver benzoates (1, 2 & 4), whilst complexes 9–12 were synthesized by generation of a free carbene
NHC∗ (1,3-dibenzyl-4,5-diphenyl-imidazol-2-ylidene) and reacting this with the silver benzoates 1–4, under
Schlenk conditions. Complexes 9–12 showed the strongest antimicrobial activity, resulting in 50% inhibition of
growth against MRSA and C. parapsilosis at concentrations of 12.5 and 3.25 µg/mL, respectively.
1. Introduction
In the fight against Antimicrobial Resistance (AMR) there is in-
creased interest in the use of silver based antimicrobials as a route to
developing new classes of drugs to overcome resistance [1,2]. Silver has
a long history in clinical medicine as a key component in burn wound
creams [3] and it has recently been shown to enhance the activity of
frontline antibiotics [4].There are few reports of prolonged resistance
[5] with only recent, isolated examples occurring after decades of use
[6].
In the last five years the growth of AMR across the world has been
highlighted in reports by the Centre for Disease Control (CDC) [7],
World Health Organisation (WHO) [8] and the European Centre for
Disease Prevention and Control (ECDC) [9]. The increasing risk of
further resistance is in part due to the over-use of antimicrobials [10]
and also the failure to develop new drugs with multiple mechanisms of
action to replace or supplement already undermined antimicrobial
compound classes [10,11]. Using the requirement of multiple me-
chanisms of action as an objective for future antimicrobial develop-
ment, silver presents an interesting element for use as a central anti-
microbial moiety. Silver sulfadiazine has been used since the early
1960s to consistently treat burn wounds [12] and it has been shown
that the bioavailability of Ag+ cations in antimicrobials is essential for
its multiple effects on microbial cells [13]. Although the mechanisms of
action have yet to be fully elucidated, in bacterial cells silver has been
shown to cause cell wall damage [14,15], intracellular protein disrup-
tion [14], stress induced seizure of DNA [14,15], disruption of bacterial
cell proton motive force [16], ATP synthesis disruption [17] and an
increase in Reactive Oxygen Species (ROS) due to iron-sulphur cluster
disruption [18].
Suitable biomolecules can be incorporated in order to enhance the
bioavailability of silver and also to act as supplementary antimicrobial
agents [19,20]. For this purpose the use of N-heterocyclic carbenes
(NHCs) and phosphines can be used to form suitably bioavailable
complexes for use as antimicrobial agents [20,21]. Previous work by
our group has highlighted the use of the lipophilic NHC* (1,3-dibenzyl-
4,5-diphenyl imidazol-2-ylidene) ligand to produce effective silver
complexes with antimicrobial activity against several strains of patho-
genic bacteria, including Methicillin-resistant Staphylococcus aureus
(MRSA) [22,23]. Along with this promising activity, the lead compound
in this class of NHC-silver(I) acetate complexes, SBC3 (Fig. 1), has
shown good activity against Candida albicans in an invertebrate in vivo
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model, demonstrating broad spectrum activity against both bacteria
and fungi [24], and demonstrating it is well tolerated in vivo. Optimi-
sation and testing of these first generation complexes [22,25] has led to
the development of eight novel silver complexes, four triphenylpho-
sphino-silver(I) benzoate complexes (5–8) and four NHC*-silver(I)
benzoate complexes (9–12). Previously it was shown that the imida-
zolium salt of our complexes produces a minor antibiotic effect [22]
and so with the incorporation of benzoates in tandem with this NHC*-
moiety it is hoped that a more pronounced antimicrobial effect will
occur.
In this work we present the synthesis and biological evaluation of
eight new silver(I) complexes and their antimicrobial activity against
the bacteria Escherichia coli and Methicillin-resistant Staphylococcus
aureus, as well as the fungi Candida albicans and Candida parapsilosis.
2. Experimental section
2.1. General details
All chemicals and solvents were used as supplied from commercial
sources without further purification or drying, unless otherwise speci-
fically stated in synthesis methods. The melting points of the corre-
sponding compounds were measured using a Stuart™ melting point
apparatus SMP10, AC input 230 V and were uncorrected. 1H, 13C, 19F
and 31P NMR spectra were obtained at room temperature on a Varian
VnmrS 400MHz spectrometer. All NMR data was collected using CDCl3
as the deuterated solvent which contains 0.03% (v/v) TMS. 1H NMR
chemical shifts were referenced to TMS; 19F and 31P chemical shifts
were relatively referenced from the corresponding 1H spectrum for the
respective compounds. Total elemental analysis was undertaken using
an Exeter Analytical CE-440 elemental analyser. Infrared spectra were
obtained using a Bruker ALPHA Platinum ATR spectrometer. Crystal
data for complexes 7–10 and 12 were collected using a Rigaku Oxford
Diffraction (former Agilent Technologies, former Oxford Diffraction)
SuperNova A diffractometer. All five were measured with Cu-Kα
(λ=1.54184 Å). A complete dataset was collected, assuming that the
Friedel pairs are not equivalent. An analytical absorption correction,
based on the shape of the crystal, was performed [35]. The structures
were solved by direct methods using SHELXS [36] and refined by full
matrix least-squares on F2 for all data using SHELXL [36]. Hydrogen
atoms were added at calculated positions and refined using a riding
model. Their isotropic temperature factors were fixed to 1.2 times the
equivalent isotropic displacement parameters of the parent atom. Ani-
sotropic thermal displacement parameters were used for all non-dis-
ordered non-hydrogen atoms. Analysis of cell culture plates for anti-
bacterial testing was undertaken using a BioTek, Synergy HT plate
reader. Analysis of cell culture plates for antifungal testing was un-
dertaken every 15min by a SynergyTM HT plate reader (BioTek In-
struments, Inc., USA).
All silver carboxylates (1–4) and triphenylphosphino silver(I)
benzoate complexes (5–8) were synthesized using adjusted synthesis
methods [26,27]. All NHC*-silver(I) benzoate complexes were
synthesized through the generation of a free carbene via the Arduengo
method [28].
2.2. Synthesis of silver benzoates (1–4)
2.2.1. Silver benzoate (1)
Benzoic acid (0.488 g, 3.00mmol) and silver(I) oxide (0.463 g,
2.00mmol) were placed in 30mL acetonitrile in a light proof flask and
stirred for 24 h. The product was filtered in vacuo, washed with 30mL
acetonitrile and dried for 4 h to retrieve a grey solid (0.540 g, 79%
yield).
1H NMR (399.89MHz, DMSO-d6, ppm): 7.12–7.08 (2H, m,
CHAromatic), 6.60–6.49 (2H, m, CHAromatic).
13C NMR (100.55MHz, DMSO-d6, ppm): 170.7, 137.2, 130.5, 129.9,
128.1.
IR (ATR): 3049 (w, v), 1586 (m), 1375 (s), 715 (s), 675 (m), 443
(m).
Melting point: 280 °C.
Elemental Analysis calculated for C7H5AgO2: Calculated: C, 36.71;
H, 2.20; Found: C, 36.00; H, 2.51.
2.2.2. Silver 2-fluoro-benzoate (2)
2-Fluorobenzoic acid (0.560 g, 3.00mmol) and silver(I) oxide
(0.463 g, 2.00mmol) were placed in 50mL acetonitrile in a light proof
flask and stirred for 24 h. The product was filtered in vacuo and washed
with 10mL acetonitrile. The solvent was removed and product dried
under reduced pressure before being extracted and washed with 20mL
diethyl ether. Product was dried for 4 h to retrieve a grey solid.
(0.824 g, 83% yield).
1H NMR (399.89MHz, DMSO-d6, ppm): 7.69 (1H, td, J=8, 2 Hz,
CHAromatic), 7.42–7.32 (1H, m, CHAromatic), 7.18–7.06 (2H, m,
CHAromatic).
13C NMR (100.55MHz, DMSO-d6, ppm): 168.4, 161.87, 131.8,
131.7, 131.4, 131.3, 124.1, 124.0, 116.6, 116.3.
19F NMR (376.24MHz, DMSO-d6, ppm): −112.4.
IR (ATR): 3075 (w, v), 1610 (m), 1586 (m), 1552 (m), 1523 (m),
1447 (m), 1376 (s), 1155 (m), 1090 (m), 857 (m), 747 (s), 657 (m), 545
(w), 446 (w).
Melting point: 230 °C.
Elemental Analysis calculated for C7H4AgO2F: Calculated: C, 34.04;
H, 1.62; Found: C, 34.20; H, 1.50.
2.2.3. Silver 3-fluoro-benzoate (3)
3-Fluorobenzoic acid (0.560 g, 3.00mmol) and silver(I) oxide
(0.463 g, 2.00mmol) were placed in 50mL acetonitrile in a light proof
flask and stirred for 24 h. The product was filtered in vacuo and washed
with 20mL acetonitrile before being washed with 20mL diethyl ether.
Product was dried for 4 h to retrieve a grey solid. (0.635 g, 64% yield).
1H NMR (399.89MHz, DMSO-d6, ppm): 7.75 (1H, dt, J=8, 1 Hz,
CHAromatic), 7.59 (1H, ddd, J=10, 3, 1.5 Hz, CHAromatic), 7.39 (1H, td,
J=8, 6 Hz, CHAromatic), 7.28–7.17 (1H, m, CHAromatic).
13C NMR (100.55MHz, DMSO‑d6, ppm): 169.2, 163.4, 161.0, 140.4,
130.1, 130.0, 125.9, 125.8, 117.3, 117.0, 116.2, 116.0.
19F NMR (376.24MHz, DMSO‑d6, ppm): −114.1.
IR (ATR): 3087 (w,v), 1561 (m), 1376 (s), 1223 (m), 790 (m), 761
(s), 437 (m).
Melting point: 250 °C.
Elemental Analysis calculated for C7H4AgO2F: Calculated: C, 34.04;
H, 1.62; Found: C, 33.55; H, 1.47.
2.2.4. Silver 4-fluoro-benzoate (4)
4-Fluorobenzoic acid (0.841 g, 6.00mmol) and silver(I) oxide
(0.695 g, 3.00mmol) were placed 50mL acetonitrile and stirred for
24 h. The product was filtered in vacuo and washed with 20mL acet-
onitrile before being washed with 20mL diethyl ether. Product was
dried for 4 h to retrieve a grey solid. (1.330 g, 90% yield).
Fig. 1. Structure of the antibiotic lead compound SBC3 [22].
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1H NMR (399.89MHz, DMSO-d6, ppm): 8.00–7.94 (2H, m,
CHAromatic), 7.15 (2H, t, J=9.0 Hz, CHAromatic).
13C NMR (100.55MHz, DMSO-d6, ppm): 169.6, 165.1, 162.7, 133.9,
132.4, 132.3, 114.9, 144.7.
19F NMR (376.24MHz, DMSO-d6, ppm): −111.99.
IR (ATR): 3068 (w, v), 1604 (m), 1499 (m), 1374 (s), 1229 (m),
1155 (m), 852 (m), 771 (s), 688 (m), 619 (s), 503 (w), 410 (w).
Melting point: 220 °C.
Elemental Analysis calculated for C7H4AgO2F: Calculated: 34.04; H,
1.62; Found: C, 33.35; H, 1.44.
2.3. Synthesis of Triphenylphosphino-silver(I) benzoate complexes (5–8)
2.3.1. Bis-triphenylphosphino-silver(I) benzoate (5)
Triphenylphosphine (0.524 g, 2.00mmol) and silver benzoate
(0.229 g, 1.00mmol) were dissolved in 20mL of dry dichloromethane.
The mixture was stirred in the absence of light for 2 d under nitrogen.
The product was filtered in vacuo and washed with 20mL of dry di-
chloromethane. The filtrate was concentrated to 2mL and 5mL of
pentane was added. The product was extracted and dried for 4 h in
vacuo to retrieve a white solid (0.596 g, 79% yield).
1H NMR (399.89MHz, CDCl3, ppm): 8.14 (4H, dd, J=8.3, 1.2 Hz,
CHAromatic), 7.53–7.48 (10H, m, CHAromatic), 7.47 (10H, d, J=3Hz,
CHAromatic), 7.46–7.41 (8H, m, CHAromatic), 7.41–7.38 (3H, m,
CHAromatic).
13C NMR (100.55MHz, CDCl3, ppm): 175.1, 134.6, 134.0, 133.8,
131.3, 131.2, 130.8, 130.0, 129.9, 129.5, 129.3, 129.2, 127.5.
31P NMR (282.11MHz, CDCl3), ppm): 29.06.
IR (ATR): 3100 (w), 2900 (w), 1592 (m), 1537 (m), 1434 (m), 1305
(m), 1131 (w), 1095 (m), 691 (s), 489 (m).
Melting Point: 62 °C.
Elemental Analysis calculated for C43H35AgO2P2: C, 68.53; H, 4.68;
A. Found: C, 68.25; H, 4.17.
2.3.2. Triphenylphosphino silver(I) 2-fluorobenzoate (6)
Triphenylphosphine (0.262 g, 1.00mmol) and 2-fluoro-silver
benzoate (0.247 g, 1.00mmol) were dissolved in 5mL of dry di-
chloromethane. The mixture stirred in the absence of light for 2 d under
nitrogen. The product was filtered in vacuo and washed with 20mL of
dry dichloromethane. The filtrate was concentrated to 2mL and 5mL of
pentane was added. The product was extracted and dried for 4 h in
vacuo to retrieve a light brown solid (0.342 g, 70% yield).
1H NMR (399.89MHz, CDCl3, ppm): 7.85 (1H, td, J=7.5, 2 Hz,
CHAromatic), 7.48–7.37 (10H, m, CHAromatic), 7.32 (7H, t, J=7Hz,
CHAromatic), 7.12–7.03 (1H, m, CHAromatic).
13C NMR (100.55MHz, CDCl3, ppm): 171.5, 162.4, 159.9, 134.0,
133.8, 130.8, 130.7, 130.3, 128.9, 128.8, 123.2, 123.3, 116.3, 115.9.
19F NMR (376.24MHz, CDCl3, ppm): −113.26.
31P NMR (282.11MHz, CDCl3), ppm): 11.22
IR (ATR): 3050 (w, v), 1591 (w), 1554 (w), 1476 (m), 1433 (m),
1370 (m), 1093 (m), 854 (m), 795 (s), 691 (s), 654 (s), 542 (s), 503 (s).
Melting Point: 110 °C.
Elemental Analysis calculated for C25H19AgO2FP: C, 58.96; H, 3.76;
Found: C, 58.78; H, 3.69.
2.3.3. Bis-triphenylphosphino silver(I) 2-fluorobenzoate (7)
Triphenylphosphine (0.524 g, 2.00mmol) and 2-fluoro-silver
benzoate (0.247 g, 1.00mmol) were dissolved in 30mL of dry di-
chloromethane. The mixture was stirred in the absence of light for 2 d
under nitrogen. The product was filtered in vacuo and washed with
20mL of dry dichloromethane. The filtrate was concentrated to 2mL
and 30mL of pentane was added. The product was extracted and dried
for 4 h in vacuo to retrieve a silver solid (0.713 g, 93% yield).
1H NMR (399.89MHz, CDCl3, ppm): 7.77 (1H, td, J=7.5, 2 Hz,
CHAromatic), 7.48–7.33 (16H, m, CHAromatic), 7.29 (15H, t, J=7.5 Hz,
CHAromatic), 7.10 – 7.00 (2H, m, CHAromatic).
13C NMR (100.55MHz, CDCl3, ppm): 171.1, 162.2, 134.0, 133.8,
132.5, 132.2, 131.6, 131.5, 130.2, 130.1, 130.0, 128.8, 128.7, 123.2,
123.1, 116.0, 115.8.
19F NMR (376.24MHz, CDCl3, ppm): −113.83.
31P NMR (282.11MHz, CDCl3), ppm): 8.74.
IR (ATR): 3049 (w, v), 1591 (m), 1555 (m), 1478 (m), 1433 (m),
1371 (m), 1026 (m), 854 (m), 741 (s), 690 (s), 501 (s).
Melting Point: 140 °C.
Elemental Analysis calculated for C43H34O2AgFP2: C, 66.93; H,
4.44; Found: C, 66.60H, 5.33.
2.3.4. Bis-triphenylphosphino silver(I) 4-fluorobenzoate (8)
Triphenylphosphine (0.524 g, 2.00mmol) and 4-fluoro-silver
benzoate (0.247 g, 1.00mmol) were dissolved in 20mL of dry di-
chloromethane. The mixture was stirred in the absence of light for 2 d
under nitrogen. The product was filtered in vacuo and washed with
20mL of dry dichloromethane. The filtrate was concentrated to 2mL
and 5mL of pentane was added. The product was extracted and dried
for 4 h in vacuo to retrieve a light brown solid (0.650 g, 84% yield).
1H NMR (399.89MHz, CDCl3, ppm): 8.11–8.02 (2H, m, CHAromatic),
7.44–7.32 (19H, m, CHAromatic), 7.27 (6H, s, CHAromatic), 7.24 (5H, d,
J=7Hz, CHAromatic), 7.04–6.95 (2H, m, CHAromatic).
13C NMR (100.55MHz, CDCl3, ppm): 173.1, 164.9, 162.4, 133.0,
132.8, 131.3, 131.2, 131.1, 130.9, 130.3, 130.3, 130.0, 130.0, 129.0,
128.6, 128.4, 128.3, 127. 5, 127.4, 113.8, 113.6.
19F NMR (376.24MHz, CDCl3, ppm): −112.72.
31P NMR (282.11MHz, CDCl3), ppm): 8.56.
IR (ATR): 3100 (w, v), 1606 (m), 1555 (m), 1478 (m), 1434 (m),
1370 (m), 1215 (m), 1146 (m), 1095 (m), 856 (m), 780 (7 8 0), 742 (s),
692 (s), 611 (s), 495 (s).
Melting Point: 152 °C.
Elemental Analysis calculated for C43H34O2AgFP2: C, 66.93; H,
4.44; Found: C, 67.16; H, 4.70.
2.4. Synthesis of 1,3-dibenzyl-4,5-diphenyl imidazol-2-ylidene silver(I)
benzoate complexes (9–12)
1mL of 1M potassium tert-butoxide solution (1.00mmol) was in-
jected at 0 °C to a mixture of 30mL dry tetrahydrofuran and 1,3-di-
benzyl-4,5-diphenyl imidazolium bromide (0.481 g, 1.00mmol), under
nitrogen. The reaction was stirred for 1 h at room temperature and al-
lowed to settle for 30min. The solution was syringed from the reaction
flask and injected into a second flask containing 30mL dry tetra-
hydrofuran and 1.00mmol of the corresponding silver benzoate; all
additions are kept under nitrogen. The reaction mixture was stirred for
3 d under nitrogen. The reaction mixture was filtered in vacuo and re-
filtered using a grade 4 sinter funnel. The filtrate was removed under
reduced pressure to retrieve a solid that was dissolved in chloroform
and filtered using a grade 4 sinter funnel. The filtrate was filtered by
gravity filtration to remove remaining impurities and concentrated to
3mL under reduced pressure. 80mL of pentane was added and the
solution was allowed to sit for 24 h. The solid product was extracted
with pentane, filtered in vacuo and dried for 4 h.
2.4.1. Synthesis of 1,3-dibenzyl-4,5-diphenyl imidazol-2-ylidene silver(I)
benzoate (9)
20mL of the carbene/THF solution is injected into a reaction flask
containing silver benzoate (0.228 g, 1.00mmol) in 30mL tetra-
hydrofuran at room temperature, whilst stirring. The reaction is stirred
for 3 d and worked up to achieve a brown solid (0.207 g, 33% yield).
1H NMR (399.89MHz, CDCl3, ppm): 8.10 (2H, d, J=8Hz,
CHAromatic), 7.44–7.34 (3H, m, CHAromatic), 7.28 (2H, t, J=7.5 Hz,
CHAromatic), 7.24–7.19 (9H, m, CHAromatic), 7.03–6.96 (8H, m,
CHAromatic), 5.38 (4H, s, CH2Benzyl).
13C NMR (100.55MHz, CDCl3, ppm): 179.7, 173.4, 136.1, 132.7,
130.6, 130.4, 129.5, 129.1, 128.6, 128.5, 127.9, 127.7, 127.3, 53.7.
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IR (ATR): 3058 (w), 1596 (w), 1565 (w), 1442 (w), 1365 (m), 1020
(w), 836 (w), 838 (w), 761 (w), 722 (m), 696 (s), 614 (w), 579 (w), 519
(w), 453 (w).
Melting point: 176 °C.
Elemental Analysis calculated for C36H29N2AgO2: Calculated: C,
68.69; H, 4.64; N, 4.45; Found: C, 68.13; H, 4.56; N, 4.23.
2.4.2. Synthesis of 1,3-dibenzyl-4,5-diphenyl imidazol-2-ylidene silver(I) 2-
fluorobenzoate (10)
20mL of the carbene/THF solution is injected into a reaction flask
containing 2-fluoro-silver benzoate (0.247 g, 1.00mmol) and 30mL
tetrahydrofuran at room temperature, whilst stirring. The reaction is
stirred for 3 d and worked up to achieve a silver solid (0.359 g, 55%
yield).
1H NMR (399.89MHz, CDCl3, ppm): 7.95–7.89 (1H, m, CHAromatic),
7.32–7.26 (3H, m, CHAromatic), 7.25–7.18 (9H, m, CHAromatic),
7.12–7.06 (2H, m, CHAromatic), 7.05–6.97 (9H, m, CHAromatic), 5.37 (4H,
s, CH2Benzyl).
13C NMR (100.55MHz, CDCl3, ppm): 179.3, 170.8, 162.7, 160.2,
136.2, 132.7, 132.5, 131.7, 131.6, 130.6, 129.1, 128.7, 128.5, 128.0,
127.6, 127.3, 123.4, 116.4, 116.1, 53.7.
19F NMR (376.24MHz, CDCl3, ppm): −112.2.
IR (ATR): 3058 (w), 1595 (m), 1549 (m), 1449 (m), 1374 (s), 1218
(m), 857 (m), 757 (s), 735 (m), 698 (s), 656 (m), 461 (w).
Melting point: 154 °C.
Elemental Analysis calculated for C36H28N2AgO2F: Calculated: C,
66.78; H, 4.36; N, 4.33; Found: C, 66.65; H, 4.25; N, 4.20.
Synthesis of 1,3-dibenzyl-4,5-diphenyl imidazol-2-ylidene silver(I)
3-fluorobenzoate (11).
20mL of the carbene/THF solution is injected into a reaction flask
containing 3-fluoro silver benzoate (0.247 g, 1.00mmol) and 30mL
tetrahydrofuran at room temperature, whilst stirring. The reaction is
stirred for 3 d and worked up to achieve a light brown solid (0.129 g,
19% yield).
1H NMR (399.89MHz, CDCl3, ppm): 7.87 (1H, d, J=7.5 Hz,
CHAromatic), 7.78 (1H, d, J=10Hz, CHAromatic), 7.30 (3H, dd, J=16,
8.5 Hz, CHAromatic), 7.23 (10H, dd, J=5.5, 2.0 Hz, CHAromatic), 7.10
(1H, t, J=8.5 Hz, CHAromatic), 7.00 (8H, d, J=7Hz, CHAromatic), 5.38
(4H, s, CHBenzyl).
13C NMR (100.55MHz, CDCl3, ppm): 179.6, 163.7, 136.1, 132.7,
130.6, 129.1, 128.7, 128.69, 128.5, 128.0, 127.6, 127.3, 125.5, 117.3,
117.1, 53.7.
19F NMR (376.24MHz, CDCl3, ppm): −114.3.
IR (KBr, cm-1): 3053 (w), 1602 (w), 1571 (m), 1438 (w), 1357 (m),
1222 (w), 795 (m), 767 (s), 696 (s), 614 (w), 444 (w).
Melting point: 164 °C.
Elemental Analysis calculated for C36H28N2AgO2F: Calculated: C,
66.78; H, 4.36; N, 4.33; Found: C, 66.26; H, 4.22; N, 4.24.
2.4.3. Synthesis of 1,3-dibenzyl-4,5-diphenyl imidazol-2-ylidene silver(I) 4-
fluorobenzoate (12)
20mL of the carbene/THF solution is injected into a reaction flask
containing 4-fluoro silver benzoate (0.247 g, 1.00mmol) and 30mL
tetrahydrofuran at room temperature, whilst stirring. The reaction is
stirred for 3 d and worked up to achieve a light brown solid (0.311 g,
48% yield).
1H NMR (399.89MHz, CDCl3, ppm): 8.10 (2H, dd, J=9, 6 Hz,
CHAromatic), 7.29 (2H, t, J=7.5 Hz, CHAromatic), 7.25–7.19 (10H, m,
CHAromatic), 7.06–6.97 (10H, m, CHAromatic), 5.38 (4H, s, CH2Benzyl).
13C NMR (100.55MHz, CDCl3, ppm): 179.6, 172.7, 166.6, 163.1,
136.1, 132.7, 132.1, 132.0, 130.6, 129.1, 128.6, 128.5, 128.0, 127.6,
127.3, 114.5, 114.3, 53.8.
19F NMR (376.24MHz, CDCl3, ppm): −111.1.
IR (ATR): 3056 (w,v), 1616 (w), 1584 (w), 1344 (m), 1209 (w),
1147 (w), 856 (m), 742 (m), 697 (s), 623 (m), 479 (w).
Melting point: 207 °C.
Elemental Analysis calculated for C36H28N2AgO2F: Calculated: C,
66.78; H, 4.36; N, 4.33; Found: C, 66.41; H, 4.38; N, 4.14.
2.5. Antimicrobial studies
2.5.1. Kirby-Bauer Disk Diffusion
In vitro screening for antibacterial efficacy was conducted using the
Kirby-Bauer Disk Diffusion method against one Gram-positive patho-
genic bacterial strain and one Gram-negative pathogenic bacterial
strain; Methicillin-resistant Staphylococcus aureus (ATCC43300) was
chosen as the Gram-positive strain and Escherichia coli (ATCC 25922)
was chosen as the Gram-negative strain [25].
Both bacterial strains were cultured in 2mL LB medium from single
colonies at 37 °C for 24 h whilst shaking. 50 μL of culture was spread
over agar-LB medium (SIGMA L2897) in a petri plate and to each plate
5.5 mm Whatman paper disks were evenly placed into four marked
quadrants. Stock solutions of the silver benzoate starting materials
(1–4) and silver complexes (5–12) were made to a 1mg/mL dilution in
DMSO. Two volumes of 5 μL and 10 μL were tested for each silver
benzoate and complex against both bacterial strains. DMSO, without
the addition of a silver complex, was used as a control in 5 μL and 10 μL
volumes; three other antibacterial compounds were also used in 1mg/
ml dilutions as comparative controls. All plates were incubated at 37 °C
for 24 h. The area of clearance is defined as the distance between the
beginning of bacterial growth and the edge of the Whatman disk; the
zone of inhibition (radius) was measured in millimetres (mm). All an-
tibacterial work was carried out under sterile conditions [32]. Single
run assays performed, no replicates were conducted as this was used as
a preliminary screening of antibiotic activity.
2.5.2. Minimum Inhibitory Concentration (MIC) – bacterial assays
Further in vitro screening against bacteria was conducted on the two
most potent complexes againstMethicillin-resistant Staphylococcus aureus
(ATCC43300). The MRSA strain was cultured to the stationary phase
(OD600= 2) in nutrient broth (OXOID CM0001) for 24 h at 37 °C, whilst
shaking.
To a 96-well cell culture plate (Sarstedt), 100 μL of nutrient broth
was added to each well. 1 mg/mL dilutions of complexes 8 and 12 were
made in DMSO, which was further diluted to a 10% DMSO solution in
deionised water. A 10% DMSO/water solution and a SBC3 NHC-silver
(I) acetate complex [22] solution in 10% DMSO/water were tested si-
multaneously as comparative controls. 100 μL of the stock silver com-
plex solutions were added to respective plates and a serial dilution was
carried out to give a concentration range of 0.39–100 μg/mL. 100 μL of
the MRSA cell suspension was added to the cell culture plates and the
plates then incubated for 24 h at 37 °C The plates were measured for
effect of inhibition using a microplate reader (BioTek, Synergy HT) at
OD570 and all growth is presented as a percentage of the control. All
assays were performed in triplicate [24].
2.5.3. Minimum Inhibitory Concentration (MIC) – fungal assays
In vitro screening against fungi was conducted on all silver com-
plexes (5–12) to determine the extent of broad spectrum activity.
Preliminary testing was carried out on cells growing in minimal media
to establish the effectiveness of both classes of silver complexes, and the
MIC values were determined using the CSLI standard method [34].
Complexes were tested against the two pathogenic fungi Candida albi-
cans SC5314 and Candida parapsilosis CLIB214 (ATCC22019).
For growth inhibition assays, complexes (5–12) were freshly made
to a 2mg/mL concentration in ethanol, and a serial dilution was per-
formed to the desired concentration range (0.15625–40 µg/mL) in
100 µL in a U-bottom 96-well (Sarstedt) plate. Both yeast species were
maintained on YPD (1% Yeast extract, 2% Peptone and 2%Dextrose)
agar plates and a single colony was inoculated to 5mL YPD broth
medium and grown overnight at 30 °C with shaking. Yeast cells were
collected and re-suspended in Yeast Nutrient Broth (YNB: 0.19% Yeast
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nitrogen base without amino acids and without ammonium sulfate
(Formedium, CYN0501), 0.5% ammonium sulfate (Sigma, A4418),
0.079% amino acids (Formedium, DCS0019) and 2% glucose) to an
optical density (A600) of 0.02. 100 μL of yeast inoculum was loaded on
top of the 100 μL drug dilutions. The A600 of the plate was read every
15min for 24 h by using a SynergyTM HT plate reader (BioTek
Instruments, Inc., USA) and recorded using the Gen5TM Microplate
Software (BioTek Instruments, Inc., USA). All results are expressed as a
% growth compared to the growth of the control. All assays were re-
plicated in quadruplicate.
The MIC values of complexes 9–12 were determined using the
standardized broth microdilution method as recommended by the CLSI
document M27-A3 (CLSI, 2008) [34]. All compounds were freshly
prepared and diluted to 40 μg/mL, 20 μg/mL, 10 μg/mL, 5 μg/mL,
2.5 μg/mL, 1.25 μg/mL, 0.625 μg/mL, 0.3 μg/mL and 0.15 μg/mL. In-
ocula were prepared from a 24 h culture on Sabouraud Dextrose agar
plate, adjusted to same absorbance of the 0.5 Mac Farland standard
(CLSI, M27-S3) at 530 nm, and diluted in RPMI-1640 (Sigma, R1383)
supplemented with 0.02% glucose (Sigma, G8720) to the desired con-
centration of 1–5× 103 colony-forming units (CFU)/ml. 100 μL of drug
dilution was mixed with 100 μL of inoculum in a U-bottom 96-well
plate and incubated at 35 °C. Plates were scored at 24 h and 48 h. The
MIC was defined as the lowest concentration of drug that inhibits 50%
growth relative to the growth in the drug-free control well after 48 h.
Commercial antifungal drugs Fluconazole (Sigma, F8929) and Caspo-
fungin (Sigma, SML0425) were tested against C. albicans SC5314, C.
parapsilosis CLIB214 (ATCC22019) and C. krusei (ATCC6258), with the
later two as references recommended by CLSI to confirm the accuracy
of the assays. All assays were replicated in quadruplicate.
3. Results & discussion
3.1. Synthesis
The synthesis of the silver carboxylates (1–4) was achieved using a
modified literature method to produce the silver benzoate and three
fluorinated silver benzoates species [26] (Scheme 1). The benzoic acid
starting materials were reacted with silver oxide in acetonitrile, in the
absence of light, to retrieve the corresponding silver benzoates (Scheme
1). The products were obtained in good yields (64–83%) with high
purity using the stated work-up.
The corresponding benzoates were used as starting materials for the
synthesis of the respective combination triphenylphosphino– and
NHC*-silver(I) complexes. Complexes 5–8 were synthesized using a
modified literature method [27] (Scheme 2), with an intermediate free
carbene generated during the synthesis of complexes 9–12 [28]
(Scheme 3). For complex 6, the 2-fluoro-silver benzoate was reacted
with 1 equivalent of triphenylphosphine for 2 d in dried di-
chloromethane, in darkness and under nitrogen (Scheme 2). For the
remaining triphenylphosphino-silver(I) benzoate complexes (5, 7, 8),
the corresponding silver carboxylates were reacted with 2 equivalents
of triphenylphosphine for 2 d in dry dichloromethane, in darkness and
under nitrogen (Scheme 2).
The NHC*-carbene silver(I) benzoate complexes (9–12) were
synthesized by first generating a free carbene from the precursor imi-
dazolium bromide salt [28], which was made in 80% yield using a
modified literature method and confirmed by spectroscopic analysis
[22,25].
Generation of the free carbene is achieved by injecting 1mL of 1M
potassium tert-butoxide in THF solution into a flask charged with 1mol
of the imidazolium bromide and 30mL dried THF, at 0 °C under ni-
trogen. After stirring for 1 h, the resulting reaction solution was then
transferred to a secondary flask containing 1 equivalent of the corre-
sponding silver benzoates (1–4) in 30mL dried THF, under nitrogen.
The reaction was stirred for 3 d at room temperature and worked up to
achieve solid products in 19–55% yield (Scheme 3). The side product of
potassium bromide is produced during the generation the free carbene
and must be allowed to settle before the solution can be transferred to
the secondary reaction flask. The use of a small reaction flask
(50–100mL) led to an increase in transferrable amount of the free
carbene solution, resulting in higher yields.
3.2. Characterisation
The synthesis of the silver carboxylates (1–4) were all confirmed by
IR spectroscopy, showing the loss of the distinctive wide carboxylic acid
‘OH’ band between 3000 and 2500 cm−1, and by elemental analysis.
Complexes 5–8 were confirmed by NMR spectroscopy (1H, 19F, 31P),
IR spectroscopy and elemental analysis. All complexes integrated to the
correct number of protons in 1H NMR, with corresponding singlet sig-
nals observed at the correct ranges in both the 19F spectra (−112 to
−113 ppm) [29] and 31P spectra (11–8 ppm) [27].
Complexes 9–12 were confirmed by NMR spectroscopy (1H, 19F), IR
spectroscopy and elemental analysis. The loss of the carbene proton
peak in the range of 10.50–11.50 ppm shows deprotonation of the NHC-
ligand in 1H NMR, and correct integration of the aromatic region was
found for the additional 5 benzyl protons of benzoate 1 and 4 benzyl
protons of benzoates 2–4. Singlet signals were found in the correct
ranges corresponding to benzyl fluorine groups (−111 to −114) in 19F
NMR [29]. 13C NMR spectra for all complexes showed additional peaks
in the range of 179.3–179.7 ppm which correspond to previous litera-
ture values for the carbene carbon after bonding with silver [22,30–34];
an additional signal is also seen for each complex between 170.8 and
173.4 ppm, which is accounting for the carbonyl carbon of the benzoate
moiety.
IR spectroscopy revealed characteristic signals for all the NHC*-Ag-
benzoates at 1374–1344 cm−1, corresponding to the carboxylate car-
bonyl carbon-oxygen double bond, and at 1222–1209 cm−1 for the
fluorinated species, corresponding to the carbon-fluorine bond.Scheme 1. Synthesis of silver benzoates 1–4.
Scheme 2. Synthesis of triphenylphosphino-silver(I) benzoate complexes 5–8.
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Crystal structures were obtained for complexes 7, 8, 9, 10 and 12,
with the structures for complexes 8 and 12 are presented in Fig. 7, as
these complexes were chosen for further antibacterial testing. Crystal
structures for complexes 7, 9 and 10 can be seen in Fig. 8, with addi-
tional data for all structures found in the Supplementary information.
3.3. Biological results
Preliminary screening to indicate the antibacterial activity of the 8
new complexes 5–12 was carried out using the Kirby-Bauer Disk
Diffusion method [25]. The following results can be seen in Figs. 2 and
3. The eight novel complexes were compared to the silver benzoates
(1–4) and three control compounds of proven antibacterial activity
(SBC3, Tetracycline and Ciprofloxacin).
Fig. 2 confirms that the proven antimicrobial compounds Tetra-
cycline and Ciproflaxin are highly effective against MRSA, producing
zones of clearance with a radius of 14mm and 12mm, respectively. The
SBC3 molecule shows the next greatest efficacy with a 5mm radius
zone of clearance, whereas complexes 10 and 12 each show similar
activity with a 4.5mm radius zone of clearance. The triphenylpho-
sphino-silver(I) benzoate complex 8 also shows similar activity to SBC3
with a zone of clearance of radius 4mm. All compounds were tested by
administering 10 µL volume of a 1mg/mL solution of the compounds in
DMSO.
Fig. 3 shows the effect of the tested compounds against E. coli.
Again, Tetracycline and Ciprofloxacin show very good activity against
the bacterium, producing 12mm and 16mm radius zones of clear-
ance, respectively. SBC3 also shows some activity against E. coli with a
4mm radius zone of clearance. Complexes 9, 11 and 12 show similar
activity to SBC3 with zones of clearance of radius 5–6 mm. However,
against E. coli the triphenylphosphino-silver(I) benzoate complexes
show little to no inhibition. This shows that, similar to the SBC3
molecule, the new NHC*-silver(I) benzoate complexes have broad
spectrum activity against both Gram-negative and Gram-positive
bacteria, showing a possible greater activity against Gram-negative
bacteria in these preliminary tests. Measurements of zones of inhibi-
tion for all tested compounds can be found in the Supplementary in-
formation.
Two complexes were chosen for further in vitro screening to de-
termine Minimum Inhibitory Concentration (MIC) [24,34]; one tri-
phenylphosphino-silver(I) benzoate complex, 8, and one NHC*-silver(I)
benzoate complex, 12. These complexes represented similar activity
against MRSA and contained the same 4-fluoro-benzoate modality, and
therefore both were tested to determine their MIC.
As can be seen in Fig. 4, all complexes inhibit growth in the higher
concentration ranges (100–25 µg/mL). However, at 25 µg/mL complex
8 inhibits growth poorly. At all concentrations the inhibitory effect of
complex 12 shows similar activity to the SBC3 molecule. At the 25 µg/
mL concentration, SBC3 shows 79% inhibition of growth while complex
12 shows 65% inhibition of growth. Inhibition of MRSA stays at below
50% at a concentrate of 6.25 µg/mL or higher; similar to previous re-
ported values for SBC3 against Methicillin-susceptible Staphylococcus
aureus [24]. Complex 12 therefore has similar antibacterial properties
to SBC3 and a possible greater effect against Gram-negative bacteria
(Fig. 3). Detailed data of the antibacterial MIC testing can be found in
the Supplementary information.
Scheme 3. Synthesis of NHC*-silver(I) benzoates complexes 9–12.
Fig. 2. Radius of zones of clearance (mm) against MRSA using 10 μL volume of 1mg/mL DMSO/ silver(I) compounds (SBC3, 1–12) solutions and 1mg/mL DMSO/
compound (Tetracycline, Ciproflaxin) solutions.
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To determine the broad spectrum ability of the new complexes
(5–12), antifungal activity was tested for against Candida albicans
SC5314 and Candida parapsilosis CLIB214 (ATCC22019). Figs. 5 and 6
present and compare the activity of the triphenylphosphino-silver(I)
benzoate complexes (5–8) with SBC3.
Fig. 5 shows that the triphenylphosphino-silver(I) benzoate com-
plexes inhibit the growth of C. albicans when administered at higher
concentrations, with complexes 5 and 6 inhibiting more than 80%
growth at 40 µg/mL. In Fig. 6, complexes 5 and 6 show more than 80%
inhibition at the 40 µg/mL concentration against C. parapsilosis. Com-
plex 6 retains a greater than 80% inhibition at 20 µg/mL concentration,
but complexes 5 and 8 show lessened activity of against C. parapsilosis
at the lower concentration of 20 µg/mL. Complex 7 shows no inhibition
greater than 40%.
For the NHC*-silver(I) benzoate complexes, 9–12, the MIC against
both C. albicans and C. parapsilosis was determined using the CLSI
standardized broth microdilution method [34]. MIC was determined as
the lowest concentration that causes 50% inhibition of growth.
Table 1 compares the MIC values for SBC3, complexes 9–12 and
two antifungal standards (Fluconazole and Caspofungin) were used as
internal references are presented; an additional control strain (Can-
dida krusei ATCC6258) was also incorporated. The MICs of the two
internal controls (Fluconazole and Caspofungin) lie within the ex-
pected ranges.
For SBC3 and complexes 9–12, there are consistent MIC values at
concentrations of 0.625 µg/mL against C. albicans and consistent MIC
values at concentrations of 0.3125 µg/mL against C. parapsilosis. Whilst
the MIC value of the silver(I) complexes is higher than that of
Caspofungin and Fluconazole against C. albicans, these silver(I) com-
plexes show inhibition at comparable concentrations to the two control
compounds against C. parapsilosis.
Fig. 3. Radius of zones of clearance (mm) against E. coli using 10 μL volume of 1 mg/mL DMSO/silver(I) compounds (SBC3, 1–12) solutions and 1mg/mL DMSO/
compound (Tetracycline, Ciproflaxin) solutions.
Fig. 4. Inhibition of MRSA growth by SBC and complexes 8 & 12.
Fig. 5. Inhibition of C. albicans growth by triphenylphosphino-silver(I)
benzoate complexes (5–8).
Fig. 6. Inhibition of C. parapsilosis growth by triphenylphosphino-silver(I)
benzoate complexes (5–8).
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3.4. Crystal structures
In Fig. 7 the structures of complexes 8 and 12 are presented. Both
crystals were obtained by the slow diffusion of pentane into a saturated
solution of the corresponding complexes in dichloromethane at -4°C. In
complex 8, the bond distances from the silver atom to both the tri-
phenylphosphine phosphorus atoms and the benzoate oxygen are si-
milar to previous literature values, as are bond angles between the
silver, phosphorus and oxygen atoms [27] (Table 2).
Similarly, the bond lengths of the silver to both the NHC*-backbone
and carboxylate oxygens of complex 12 show comparable bond dis-
tances to previously reported NHC*-silver(I) complexes by our group
[22,30–33] (Table 2), despite the incorporation of the new benzoate
group. However, in complex 12 the bond angle between the NHC, silver
atom and carboxylate oxygen is more linear than previous NHC*-silver
(I) complexes at an angle of 178.86(6)° [22,30–33]. Comparatively,
complex 8 adopts an η1+1 coordination between the carboxylate oxy-
gens, as the second interaction between the silver atom and the car-
bonyl oxygen has too great a distance to be considered a bond (2.724(2)
pm), and can more correctly be characterised as a ‘long contact’ in-
teraction. Complex 12 remains in η1 coordination, despite the same
fluorinated benzoate substituent in both of these complexes.
In Fig. 8, the structures for complexes 7, 9 and 10 are presented. In
the crystal structure of complex 7, there is definitive η2 bonding seen
between both oxygens of the benzoate and silver atom, showing dis-
tances of similar lengths at 2.5559(13) and 2.4349(13) Å for both the
silver-oxygen bonds, Ag–O(1) and Ag–O(2), respectively. Bond lengths
and angles for the phosphorus-silver bond are also similar and con-
sistent with complex 8 and literature values [27]. In the structures of
complexes 9 and 10, bond lengths for the carbene carbon bond to silver
and silver to benzoate oxygen remain very similar to complex 12. The
major difference between these complexes is the less linear character of
Fig. 7. Crystal structures of complex 8 and complex 12; thermal ellipsoids are drawn on a 50% probability level for both structures.
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the bonding between the carbene carbon, the silver centre and the
benzoate oxygen, which is calculated at 174.94(8)° and 175.60(17)o for
complexes 9 and 10, respectively. All crystallographic data can be
found in the Supplementary information.
4. Conclusions
Four triphenylphosphino-silver(I) benzoate complexes and four 1,3-
dibenzyl-4,5-diphenyl imidazol-2-ylidene silver(I) benzoate complexes,
Fig. 8. Crystal structures of complexes 7, 9 and 10; thermal ellipsoids are drawn on a 50% probability level for all three structures.
Table 1
MIC values of complexes 9–12 against C. albicans and C. parapsilosis (NT=not
tested).
MIC (µg/mL)
C. albicans SC5314 C. parapsilosis CLIB214 C. krusei ATCC6258
Fluconazole 0.125 0.5 16
Caspofungin 0.25 2 2
SBC3 0.625 0.3125 NT
9 0.625 0.3125 NT
10 0.625 0.3125 NT
11 0.625 0.3125 NT
12 0.625 0.3125 NT
Table 2
Selected bond lengths and angles for complexes 8 and 12.
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were successfully synthesised from either triphenylphosphine or the
free NHC* ligand. Their biological activity was evaluated against
MRSA, E. coli, C. albicans and C. parapsilosis allowing to identify anti-
biotic drug candidates.
Against the bacterial strains, all complexes induce some inhibitory
effect in Kirby-Bauer Disk Diffusion testing against MRSA, with the
NHC*-silver(I) benzoate complexes showing the most promising anti-
bacterial activity. In the Kirby-Bauer testing, all NHC*-silver(I)
benzoate complexes 9–12 show equal activity to the SBC3 molecule
against the Gram-positive bacteria MRSA and against the Gram-nega-
tive bacteria E. coli, demonstrating broad spectrum activity equal to
SBC3. The NHC*-silver(I) benzoate complex 12 also completely inhibits
growth at a concentration of 12.5 µg/mL, similar to that of SBC3 against
MRSA.
The antifungal activity of complexes 5–12 against C. albicans and C.
parapsilosis was also determined. Preliminary testing was conducted
using a similar method to that of the antibacterial testing, and the MICs
of complexes 9–12 were determined by retesting and using the CLSI
standardized broth microdilution method. These results showed that
SBC3 and all the NHC*–silver(I) benzoate complexes had a similar in-
hibitory effect against C. parapsilosis to the clinical standards
Caspofungin and Fluconazole.
From these results we can see that the NHC*-silver(I) benzoate
complexes may be an interesting and effective new class of anti-
microbials to be explored and an improvement on previous NHC-silver
(I) acetate complexes, such as SBC3, against Gram-negative bacteria,
though this is to explored in future work.
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